Chugai Pharmaceutical Co., Ltd.
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Chugai Pharmaceutical Co., Ltd.'s past years’ income statements indicate that its last revenue has decreased compared to the previous period by 12% to $1,111,367,000,000. Profit margin reached 29%. Total operating expenses were $258,887,000,000.
Profit Margin
| 2014 | 461.10B | 50.98B | 11.06% |
|---|---|---|---|
| 2015 | 498.83B | 61.12B | 12.25% |
| 2016 | 491.78B | 53.59B | 10.9% |
| 2017 | 534.19B | 72.71B | 13.61% |
| 2018 | 579.78B | 92.48B | 15.95% |
| 2019 | 686.18B | 157.56B | 22.96% |
| 2020 | 786.94B | 214.73B | 27.29% |
| 2021 | 999.75B | 302.99B | 30.31% |
| 2022 | 1.25T | 374.42B | 29.72% |
| 2023 | 1.11T | 325.47B | 29.29% |
CHGCY Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 1.11T | 1.25T | 999.75B | 786.94B | 686.18B | 579.78B | 534.19B | 491.78B | 498.83B | 461.10B |
Cost of revenue | 413.30B | 476.25B | 338.14B | 273.46B | 266.07B | 262.84B | 254.17B | 247.94B | 240.23B | 218.07B |
Gross profit | 698.06B | 783.69B | 661.61B | 513.48B | 420.11B | 316.94B | 280.02B | 243.83B | 258.60B | 243.03B |
Operating exp. | ||||||||||
Research and development | 174.86B | 149.62B | 137.29B | 117.85B | 107.94B | 99.20B | 92.94B | 85.01B | 83.79B | 80.8B |
Selling and marketing | 112.58B | 77.14B | 76.59B | 72.58B | 77.18B | 73.70B | 72.8B | 69.77B | 74.81B | 71.74B |
Total operating expenses | 258.88B | 250.38B | 239.71B | 212.25B | 209.51B | 192.61B | 181.09B | 166.95B | 171.81B | 167.17B |
Operating income | 439.17B | 533.30B | 421.89B | 301.23B | 210.59B | 124.32B | 98.93B | 76.88B | 86.78B | 75.85B |
Other income (expenses), net | 4.64B | -2.14B | -2.51B | -3.04B | -2.70B | -2.87B | -1.90B | -2.43B | 492M | 305M |
Income before tax | 443.82B | 531.16B | 419.38B | 298.18B | 207.89B | 121.44B | 97.03B | 74.44B | 87.27B | 76.16B |
Income tax expense | 118.34B | 156.73B | 116.39B | 83.45B | 50.33B | 28.37B | 23.49B | 20.07B | 24.92B | 24.08B |
Net income | 325.47B | 374.42B | 302.99B | 214.73B | 157.56B | 92.48B | 72.71B | 53.59B | 61.12B | 50.98B |
Earnings per share | ||||||||||
Basic EPS | 197.8 | 227.64 | 184.29 | 130.66 | 95.95 | 28.12 | 22.17 | 16.35 | 18.67 | 15.59 |
Diluted EPS | 197.8 | 227.57 | 184.17 | 130.53 | 95.81 | 28.12 | 22.14 | 16.33 | 18.63 | 15.56 |